Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. Viewhere

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRXB.L Regulatory News (RXB)

  • There is currently no data for RXB

Rex Bionics plc & Deltason establish partnership

22 Apr 2015 07:06

RNS Number : 9509K
Rex Bionics PLC
22 April 2015
 

22 April 2015

 

 

Rex Bionics plc

("Rex Bionics" or the "Company")

 

 Rex Bionics plc and Deltason establish partnership to commercialise the REX Robot in Hong Kong

 

Rex Bionics plc, the pioneer of the REX Robot technology that enhances the mobility of wheelchair users and Deltason Medical Ltd, a distributor of rehabilitation equipment in Hong Kong and China, are pleased to announce that they have signed a distribution agreement in which Deltason will exclusively represent REX in Hong Kong, both in neuro-rehabilitation clinics and in the personal use market.

Deltason will launch REX at the Hong Kong International Medical Devices and Supplies Fair (May 18-20 2015.)

Based on data from the World Health Organisation, the Company estimates that more than 2,000 Hong Kong citizens live with a spinal cord injury.1 

Crispin Simon, Chief Executive, Rex Bionics plc said: "We are delighted with our partnership with Deltason. Hong Kong is an important market - both in itself and for the leadership of its leading clinicians and researchers - and Deltason has an excellent reputation for service and innovation; as well as long-standing relationships in the rehabilitation community.

"We are in discussion with distribution partners of a similar quality in other countries and plan to establish coverage in other important markets over the next 24 months."

Tommy Chan, Director, Deltason Medical Ltd said: "We are very pleased to have been chosen as REX's representative in Hong Kong and believe that there is a great opportunity here for this exciting technology."

For further information please contact:

 

Rex Bionics Plc

Crispin Simon, Chief Executive Officer

+44 (0) 748 3 167851

Peter Worrall, Chief Financial Officer

+44 (0) 142 864 5416

 

Stifel Nicolaus Europe Limited (NOMAD and Broker)

Jonathan Senior/Giles Balleny

+44 (0) 20 7710 7600

 

 

Consilium Strategic Communications

Mary-Jane Elliott / Jessica Hodgson / Chris Welsh / Lindsey Neville

rexbionics@consilium-comms.com

+44 (0) 203 709 5700

 

About Deltason

Deltason Medical Limited is a 20-year old, well established distributor of rehabilitation equipment in Hong Kong, China and has a strong presence in neurology and stroke rehabilitation. Deltason is headquartered in Hong Kong, China with approximately 80 employees, a sub branch office at Beijing, 30 direct sales representatives and over 30 local sub-dealers throughout mainland China. Deltason is the distributor for more than 30 rehabilitation product lines developed by some of the global industry leaders, and focuses on marketing innovative products to healthcare professionals who demand superior quality. Over the years, Deltason has established a reputation of rigorous quality, unique products, profound knowledge and excellent customer service.

 

About Rex Bionics

Rex Bionics (AIM: RXB) is the UK AIM-listed pioneer of the REX Robot that enhances the mobility of wheel-chair users. Founded in Auckland, New Zealand by two robotics engineers with first-hand experience of wheelchair users and their needs, Rex Bionics is working with physiotherapists to develop the practice of Robot-Assisted Physiotherapy (RAP). In a session of RAP, REX lifts patients from a sitting position into a robot-supported standing position, allowing them to take part in a set of supported walking and stretching exercises, designed by specialist physiotherapists. 

Wheelchair users are at risk of developing numerous medical complications from extended periods of sitting. By enabling them to spend more time standing, walking and exercising, REX may offer significant health benefits, including improved sleep, cardiovascular performance, maintenance of joint range, and a reduction in common abdominal problems and prescription drug use. A programme of clinical trials is now under way to evaluate these potential benefits. 

REX can be used by people with complete spinal cord injury, as well as people who have suffered a stroke or other traumatic brain injury; and people with multiple sclerosis and muscular dystrophy. REX P, for use in the home, enables users to walk and stand with their hands free - providing more work and recreation options. 

In May 2014, Rex Bionics joined AIM with a fundraising of £10 million (gross) to scale up production, distribution and marketing internationally, in order to support growing demand for both REX products as well as developing the next generation of REX devices, REX 3.

REX is not approved for At-Home use in the United States of America.

 

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCLIFIRSSIFFIE
12
Date   Source Headline
30th May 20177:30 amRNSSuspension - Rex Bionics Plc
26th May 20174:31 pmRNSHolding(s) in Company
26th May 20177:00 amRNSCompletion of Business Transfer & Refinancing
25th May 201710:39 amRNSHoldings in Company
25th May 201710:38 amRNSHoldings in Company
22nd May 201712:23 pmRNSResults of General Meeting
3rd May 20177:00 amRNSRestructuring and New Investment
13th Mar 20177:00 amRNSFunding and strategic review update
23rd Jan 20177:00 amRNSREX initiates RAPPER III MS clinical trial
5th Dec 20167:00 amRNSInterim Results for six months ending 30 Sept 2016
18th Nov 20167:00 amRNSPresentation of REX Case Report at SCI Conference
7th Nov 20169:47 amRNSPositive Update from Rapper II Clinical Trial
24th Oct 20167:00 amRNSStroke & Brain Injury Clinical Trial in Australia
27th Sep 20161:00 pmRNSDirectors Interests
27th Sep 201612:57 pmRNSResults of Annual General Meeting
19th Sep 201610:57 amRNSRetirement of Director
1st Sep 20165:42 pmRNSPosting of Annual Report and Accounts
26th Aug 20167:00 amRNSAudited results for the year ended 31 March 2016
18th Aug 20167:00 amRNSMore Positive Data from RAPPER II
5th Aug 20162:14 pmRNSConfirmation of Strategic Investment by Maxhealth
1st Aug 201610:36 amRNSResults of General Meeting
22nd Jul 201612:00 pmRNSPosting of Supplementary Circular
18th Jul 20167:00 amRNSProposed Fundraising & General Meeting Adjournment
29th Jun 20169:30 amRNSProposed Fundraising and Notice of General Meeting
18th Mar 20162:30 pmRNSAppointment of Joint Broker
16th Mar 20167:00 amRNSTrading Update
11th Mar 20167:00 amRNSAgreement with the United States Army
19th Jan 20167:00 amRNSGrant of options
11th Jan 20167:00 amRNSJoseph A. Cucolo to join Rex Bionics Board
9th Dec 20156:04 pmRNSGrant of options
8th Dec 20157:00 amRNSInterim Results for 6 months ending 30 Sept 2015
27th Nov 20157:00 amRNSRex Bionics Positive Interim Data from RAPPER II
12th Oct 20157:00 amRNSRex Bionics Plc - Company Update
18th Sep 20157:00 amRNSLegal cases providing funding for REX
28th Aug 20157:00 amRNSResult of AGM
11th Aug 20159:54 amRNSHolding(s) in Company
10th Aug 20152:30 pmRNSHolding(s) in Company
4th Aug 20157:01 amRNSNew RexLink Software captures Robot Movement Data
20th Jul 20157:00 amRNSAnnouncement of partnership agreement with MAAB
8th Jul 20154:00 pmRNSTR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
30th Jun 201511:31 amRNSResult of EGM
12th Jun 201511:06 amRNSProposed Fundraising and Notice of General Meeting
1st Jun 20157:00 amRNSFirst Patient Treated in RAPPER II Clinical Trial
29th May 20156:36 pmRNSCORRECTION Audited Results period ended31 Mar 2015
29th May 20154:25 pmRNSAudited results for period ending 31 Mar 2015
15th May 20157:00 amRNSRex announces Distribution Agreements in Europe
14th May 201510:00 amRNSREX to showcase at ISCoS and ASIA, Montreal
6th May 20157:02 amRNSMemorandum of Understanding signed
22nd Apr 20157:06 amRNSRex Bionics plc & Deltason establish partnership
15th Apr 20157:00 amRNSUpcoming Presentations to Private Investors
12

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.